The drug was developed for patients with mild cognitive impairment, not severe dementia, and intended to slow progression of Alzheimer’s disease — not just ease symptoms.The FDA has not approved a novel therapy for Alzheimer’s disease since 2003.’We have to really temper expectations’The FDA approved aducanumab, also known as Aduhelm, using its “accelerated approval” program, which allows for the earlier approval of a drug for a serious or life-threatening illness even though more study into the drug’s benefits may be